Understand the source comparison
Hexarelin FAQ: Comparison of Growth Hormone Secretagogues
Different GH secretagogues demonstrate distinct receptor binding profiles and secondary signaling effects that determine their suitability for specific research applications. Hexarelin GHS-R1a (ghrelin receptor) 10–15× baseline CD36 scavenger receptor (cardiop
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different GH secretagogues demonstrate distinct receptor binding profiles and secondary signaling effects that determine their suitability for specific research applications.
- Hexarelin
- GHS-R1a (ghrelin receptor)
- 10–15× baseline
- CD36 scavenger receptor (cardioprotection, metabolic signaling)
- Minimal tachyphylaxis over 4–6 weeks
- Cardiovascular protection models, extended GH dynamics studies, metabolic substrate research
- GHRP-6
- 6–8× baseline
- Strong appetite stimulation via hypothalamic ghrelin pathways
- Moderate. Response decreases 20–30% after 3–4 weeks
- Appetite regulation studies, short-cycle GH release protocols
- GHRP-2
- 7–10× baseline
- Moderate cortisol and prolactin elevation at higher doses
- Moderate. Similar to GHRP-6
- General GH secretion research, dose-response curve studies
- Ipamorelin
- 5–7× baseline
- Minimal. Highly selective for GH without cortisol/prolactin elevation
- Low. Maintains response fidelity across 8–12 weeks
- Selective GH research, protocols requiring minimal off-target effects
- MK-677 (Ibutamoren)
- 4–6× baseline sustained over 24 hours
- Appetite stimulation, sleep architecture modulation
- Very low. Oral bioavailability allows chronic dosing
- Long-duration GH elevation studies, oral administration models
- Bottom Line: Hexarelin's dual GHS-R1a and CD36 receptor activity makes it uniquely suited for research examining growth hormone dynamics alongside cardiovascular or metabolic endpoints. Researchers prioritizing selective GH release without secondary signaling should consider ipamorelin, while those investigating appetite regulation mechanisms benefit from GHRP-6's strong ghrelin pathway activation. The reduced desensitization profile of hexarelin allows extended observation periods without the rapid tachyphylaxis that limits GHRP-2 and GHRP-6 protocols to 3–4 week cycles.